Schonfeld Strategic Advisors LLC

Position in CCCC — C4 Therapeutics, Inc.

CIK 1665241 NEW YORK, NY

Back to CCCC Full portfolio

Position in CCCC

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$62,972

-$515,469 QoQ

Shares Held

23,944

-76.6% QoQ

Ownership

0.019%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2021

6 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in CCCC Over Time

Shares Held

Position Value (USD)

Derivatives in CCCC

reported options exposure · as of Mar 31, 2022

CallValue

$1,213,000

CallShares

50,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Schonfeld Strategic Advisors LLC holds $420,669,608 across 133 Biotechnology names.

#	Ticker	Company	Shares	Value (USD)
1	INBX	Inhibrx Biosciences, Inc.	697,586	$66,096,273
2	AGIO	Agios Pharmaceuticals, Inc.	520,083	$19,300,280
3	JAZZ	Jazz Pharmaceuticals plc	77,272	$18,620,233
4	VRDN	Viridian Therapeutics, Inc.\DE	793,508	$14,576,741
5	MBX	MBX Biosciences, Inc.	248,670	$13,726,584
6	XENE	Xenon Pharmaceuticals Inc.	227,330	$13,721,638
7	PTCT	Ptc Therapeutics, Inc.	147,425	$12,025,457
8	INSM	INSMED Inc	104,378	$11,128,782

All Filings in CCCC

Export CSV

7 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$62,972	23,944	-76.6%	Shares	Sole	2026-05-15
2023-12-31	$578,441	102,379	+329.1%	Shares	Sole	2024-02-14
2022-09-30	$209,260	23,861	-73.4%	Shares	Sole	2022-11-14
2022-03-31	$2,175,200	89,662	+98.8%	Shares	Sole	2022-05-16
2022-03-31	$1,213,000	50,000	—	Call	Sole	2022-05-16
2021-12-31	$1,452,606	45,112	-27.5%	Shares	Sole	2022-02-14
2021-09-30	$2,781,464	62,253	—	Shares	Sole	2021-11-16
No filing history on record for this holder in this stock.